SCHEMBL30891758

SCHEMBL30891758

COc1cc2c(-c3ccc(NC(=O)Cc4ccc(C(F)(F)F)cc4)cc3)ncnc2cc1OC[C@@H]1CCNC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 6/20 0.47
▸ KDR P35968 3/20 0.45
▸ PDGFRB P09619 5/20 0.43
▸ FLT4 P35916 5/20 0.43
▸ RAF1 P04049 2/20 0.43
▸ BRAF P15056 2/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ CSF1R P07333 3/20 0.42
▸ RET P07949 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ DDR1 Q08345 1/20 0.42
▸ AURKA O14965 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ FLT3 P36888 3/20 0.42
▸ EGFR P00533 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ FLT1 P17948 1/20 0.42
▸ AXL P30530 1/20 0.41
▸ TYRO3 Q06418 1/20 0.41
▸ MERTK Q12866 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891793 1.00 KIT (0.47) KITKDRPDGFRBFLT4RAF1
SCHEMBL26101744 1.00 KIT (0.47) KITKDRPDGFRBFLT4RAF1
SCHEMBL26099914 1.00 KIT (0.47) KITKDRPDGFRBFLT4RAF1
SCHEMBL26099909 1.00 KIT (0.47) KITKDRPDGFRBFLT4RAF1
SCHEMBL30393873 0.96 KIT (0.48) KITKDRPDGFRBFLT4RAF1
SCHEMBL30891761 0.96 KIT (0.48) KITKDRPDGFRBFLT4RAF1
SCHEMBL29238331 0.96 KIT (0.48) KITKDRPDGFRBFLT4RAF1
SCHEMBL30891762 0.96 KIT (0.48) KITKDRPDGFRBFLT4RAF1
SCHEMBL29238234 0.96 KIT (0.48) KITKDRPDGFRBFLT4RAF1
SCHEMBL26100776 0.96 KIT (0.48) KITKDRPDGFRBFLT4RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB KIT 2/4885KDR 5/4885PDGFRB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback